Loading, Please Wait...
WALTHAM, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) -- Great Elm Capital Group, Inc. (NASDAQ: GEC, “Great Elm”) announced its financial results for the quarter and year ended June 30, 2019. Great Elm will host a conference call and webcast on Friday, September 13, 2019 at 8:00 a.m. Eastern Time to discuss its fourth quarter 2019 financial results. Please see below for details.
Select highlights from the fourth quarter and full fiscal year 2019 include:
“We will continue to invest in the DME business to support ongoing organic growth as well as to pursue the numerous identified acquisition opportunities that we believe offer a compelling strategic fit,” remarked Peter A. Reed, Great Elm’s Chief Executive Officer. “Furthermore, with a positive trend in management fee revenue, we believe our Investment Management business is poised for free cash flow growth in the coming year.”
Alignment of Interest
The employees of Great Elm and Great Elm Capital Management, Inc. (“GECM”) collectively own approximately 2.0 million shares of GEC stock, representing approximately 8% of its outstanding shares.1 Additionally, the directors of Great Elm collectively own or manage greater than 11% of Great Elm’s shares.1 Altogether, insiders collectively own or manage approximately 19% of the company’s outstanding shares, which Great Elm believes fosters a strong alignment of interest between employees, directors and the company’s shareholders.
BUSINESS OVERVIEW
Great Elm is a diversified, publicly-traded holding company that seeks to build long-term shareholder value across three verticals: Operating Companies, Investment Management and Real Estate.
Operating Companies
In the three and approximately 10 months ended June 30, 2019, DME generated $2.8 million and $10.4 million, respectively, of adjusted EBITDA. During the fourth quarter, DME experienced approximately 19.8% growth in PAP patient setups and meaningful revenue growth in major product categories. Management anticipates growth in both revenue and adjusted EBITDA in fiscal year 2020, supported by encouraging key performance indicators.
In June 2019, a subsidiary of Great Elm DME, Inc. acquired the respiratory assets of Midwest Respiratory Care, Inc. (“MRC”) for approximately $6.3 million or 4.6x MRC’s EBITDA less capital expenditures for the twelve months ended April 30, 2019. The team continues to pursue M&A opportunities with complementary product profiles that increase market penetration and extend existing geographic markets.
In addition to the DME business, the Great Elm team continues to evaluate acquisition opportunities across multiple industries in partnership with industry experts and/or operating executives.
Investment Management
Great Elm’s management team believes the Investment Management business is scalable, offers attractive margins and, when coupled with growth in assets under management, provides for the potential to generate incremental EBITDA.
Great Elm intends to grow assets under management through capital raises and M&A. Growth in assets under management is expected to result in increased management fee revenue for GECM. This increase in management fee revenue should drive future free cash flow generation, aided by the termination of the Full Circle consulting agreement in November 2019.
Alongside Great Elm Capital Corp., Great Elm Opportunities Fund I, LP and existing separately managed accounts, Great Elm continues to seek avenues for growth, potentially launching additional private funds and pursuing opportunistic acquisitions in the business development company space.
Real Estate
Great Elm continues to focus on credit tenant lease financings and ground lease structures across a variety of commercial, government and other properties. Great Elm’s substantial tax assets can make it a value-added partner or lessor.
FINANCIAL REVIEW: SEGMENT FINANCIALS
As of June 30, 2019, Great Elm had four operating segments: Durable Medical Equipment, Investment Management, Real Estate and General Corporate.
Durable Medical Equipment
Three and Approximately 10 Months Ended June 30, 2019:
Revenue:
Net Income (Loss):
Adjusted EBITDA:
Investment Management
Three and 12 Months Ended June 30, 2019:
Revenue:
Net Income (Loss):
Adjusted EBITDA:
Real Estate
Three and 12 Months Ended June 30, 2019:
Revenue:
Net Income (Loss):
Adjusted EBITDA:
General Corporate
Three and 12 Months Ended June 30, 2019:
Revenue:
Net Income (Loss):
Adjusted EBITDA:
Conference Call & Webcast
Great Elm will host a conference call and webcast on Friday, September 13, 2019 at 8:00 a.m. Eastern Time to discuss its fourth quarter 2019 financial results.
All interested parties are invited to participate in the conference call by dialing +1 (844) 559-0750; international callers should dial +1 (647) 689-5386. Participants should enter the Conference ID 6973727 when asked. For a copy of the slide presentation that will be referenced during the course of our conference call, please visit: https://www.greatelmcap.com/events-and-presentations/default.aspx.
The conference call will be webcast simultaneously at: https://event.on24.com/wcc/r/2021163/6EE1FE643E7E50686C8FA475B2B776A7.
About Great Elm Capital Group, Inc.
Great Elm is a publicly-traded holding company that seeks to build a business across three operating verticals: Operating Companies, Investment Management and Real Estate. Great Elm’s website can be found at www.greatelmcap.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements in this press release that are “forward-looking” statements, including statements regarding expected growth, profitability, free cash flow and outlook involve risks and uncertainties that may individually or collectively impact the matters described herein. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and represent Great Elm’s assumptions and expectations in light of currently available information. These statements involve risks, variables and uncertainties, and Great Elm’s actual performance results may differ from those projected, and any such differences may be material. For information on certain factors that could cause actual events or results to differ materially from Great Elm’s expectations, please see Great Elm’s filings with the SEC, including its most recent annual report on Form 10-K and subsequent reports on Forms 10-Q and 8-K. Additional information relating to Great Elm’s financial position and results of operations is also contained in Great Elm’s annual and quarterly reports filed with the SEC and available for download at its website www.greatelmcap.com or at the SEC website www.sec.gov.
Non-GAAP Financial Measures
The SEC has adopted rules to regulate the use in filings with the SEC, and in public disclosures, of financial measures that are not in accordance with US GAAP, such as adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”). Adjusted EBITDA is derived from methodologies other than in accordance with US GAAP. Great Elm believes that Adjusted EBITDA is an important measure for investors to use in evaluating Great Elm’s businesses. In addition, Great Elm’s management reviews Adjusted EBITDA as they evaluate acquisition opportunities.
Adjusted EBITDA has limitations as an analytical tool, and you should not consider it either in isolation from, or as a substitute for, analyzing Great Elm’s results as reported under US GAAP. Non-GAAP financial measures reported by Great Elm may not be comparable to similarly titled amounts reported by other companies.
Set forth below is a reconciliation of Adjusted EBITDA to the most directly comparable US GAAP financial measure, net income. The information in the table below includes forecasts, projections and other predictive statements that represent Great Elm’s assumptions and expectations in light of currently available information. These forecasts, projections and other predictive statements involve risks, variables and uncertainties. Great Elm’s actual performance results may differ from those projected in in the table below, and any such differences may be material.
_______________
1 This includes restricted shares that are subject to both performance and service vesting and is based on the share count pro forma for the vesting of such restricted shares.
2 Our Real Estate business began in March 2018 and there was no related activity prior to that date.
For the three months ended June 30, 2019 | ||||||||||||||||||||
(Dollar amounts in thousands) |
Durable Medical Equipment(1) |
Investment Management |
Real Estate |
General Corporate(2) |
Total | |||||||||||||||
Net income (loss) - GAAP | $ | (1,016 | ) | $ | (136 | ) | $ | 64 | $ | 41 | $ | (1,047 | ) | |||||||
EBITDA: | ||||||||||||||||||||
Net income (loss) - GAAP | $ | (1,016 | ) | $ | (136 | ) | $ | 64 | $ | 41 | $ | (1,047 | ) | |||||||
Net income from discontinued operations | - | - | - | 50 | 50 | |||||||||||||||
Interest | 1,050 | 45 | 660 | - | 1,755 | |||||||||||||||
Taxes | - | - | - | (953 | ) | (953 | ) | |||||||||||||
Depreciation and amortization | 2,033 | 178 | 431 | - | 2,642 | |||||||||||||||
EBITDA | $ | 2,067 | $ | 87 | $ | 1,155 | $ | (862 | ) | $ | 2,447 | |||||||||
Adjusted EBITDA: | ||||||||||||||||||||
EBITDA | $ | 2,067 | $ | 87 | $ | 1,155 | $ | (862 | ) | $ | 2,447 | |||||||||
Stock based compensation | - | (80 | ) | - | 114 | 34 | ||||||||||||||
Dividend income from GECC | (88 | ) | - | - | (402 | ) | (490 | ) | ||||||||||||
Unrealized (gain) loss on investment in GECC | (116 | ) | - | - | (749 | ) | (865 | ) | ||||||||||||
Unrecognized incentive fees earned(3) | - | 749 | - | - | 749 | |||||||||||||||
Severance costs | 8 | - | - | 3 | 11 | |||||||||||||||
Location start up expense | 103 | - | - | - | 103 | |||||||||||||||
Durable medical equipment management and monitoring fees | 94 | - | - | (69 | ) | 25 | ||||||||||||||
Changes in revenue reserve estimates related to system conversions(4) | 231 | - | - | - | 231 | |||||||||||||||
Equipment sold outside of predominant use(4) | 354 | - | - | - | 354 | |||||||||||||||
Finalization of purchase accounting valuations(4) | (43 | ) | - | - | - | (43 | ) | |||||||||||||
Acquisition and integration related costs(5) | 218 | - | - | 401 | 619 | |||||||||||||||
Adjusted EBITDA | $ | 2,828 | $ | 756 | $ | 1,155 | $ | (1,564 | ) | $ | 3,175 | |||||||||
For the year ended June 30, 2019 | ||||||||||||||||||||
(Dollar amounts in thousands) |
Durable Medical Equipment(1) |
Investment Management |
Real Estate |
General Corporate |
Total | |||||||||||||||
Net income (loss) - GAAP | $ | (1,107 | ) | $ | (995 | ) | $ | 191 | $ | (1,220 | ) | $ | (3,131 | ) | ||||||
EBITDA: | ||||||||||||||||||||
Net loss - GAAP | $ | (1,107 | ) | $ | (995 | ) | $ | 191 | $ | (1,220 | ) | $ | (3,131 | ) | ||||||
Net income from discontinued operations | - | - | - | (3,736 | ) | (3,736 | ) | |||||||||||||
Interest | 3,415 | 180 | 2,655 | - | 6,250 | |||||||||||||||
Taxes | - | - | - | (2,182 | ) | (2,182 | ) | |||||||||||||
Depreciation and amortization | 6,873 | 631 | 1,729 | - | 9,233 | |||||||||||||||
EBITDA | $ | 9,181 | $ | (184 | ) | $ | 4,575 | $ | (7,138 | ) | $ | 6,434 | ||||||||
Adjusted EBITDA: | ||||||||||||||||||||
EBITDA | $ | 9,181 | $ | (184 | ) | $ | 4,575 | $ | (7,138 | ) | $ | 6,434 | ||||||||
Stock based compensation | - | 521 | - | 457 | 978 | |||||||||||||||
Dividend income from GECC | (717 | ) | - | - | (1,714 | ) | (2,431 | ) | ||||||||||||
Unrealized (gain) loss on investment in GECC | 894 | - | - | 168 | 1,062 | |||||||||||||||
Unrecognized incentive fees earned(3) | - | 2,793 | - | - | 2,793 | |||||||||||||||
Severance costs | 8 | 46 | - | 208 | 262 | |||||||||||||||
Location start up expense | 161 | - | - | - | 161 | |||||||||||||||
Durable medical equipment management and monitoring fees | 217 | - | - | (134 | ) | 83 | ||||||||||||||
Changes in revenue reserve estimates related to system conversions(4) | - | - | - | - | - | |||||||||||||||
Equipment sold outside of predominant use(4) | - | - | - | - | - | |||||||||||||||
Finalization of purchase accounting valuations(4) | (143 | ) | - | - | - | (143 | ) | |||||||||||||
Acquisition and integration related costs(5) | 769 | - | - | 2,051 | 2,820 | |||||||||||||||
Adjusted EBITDA | $ | 10,370 | $ | 3,176 | $ | 4,575 | $ | (6,102 | ) | $ | 12,019 | |||||||||
For the three months ended June 30, 2018 | ||||||||||||||||||||
(Dollar amounts in thousands) |
Durable Medical Equipment(1) |
Investment Management |
Real Estate |
General Corporate(2) |
Total | |||||||||||||||
Net income (loss) - GAAP | $ | - | $ | (1,378 | ) | $ | 60 | $ | (1,214 | ) | $ | (2,532 | ) | |||||||
EBITDA: | ||||||||||||||||||||
Net income (loss) - GAAP | $ | - | $ | (1,378 | ) | $ | 60 | $ | (1,214 | ) | $ | (2,532 | ) | |||||||
Net loss from discontinued operations | - | - | - | 10 | 10 | |||||||||||||||
Interest | - | 43 | 668 | - | 711 | |||||||||||||||
Taxes | - | - | - | (147 | ) | (147 | ) | |||||||||||||
Depreciation and amortization | - | 136 | 425 | 1 | 562 | |||||||||||||||
EBITDA | $ | - | $ | (1,199 | ) | $ | 1,153 | $ | (1,350 | ) | $ | (1,396 | ) | |||||||
Adjusted EBITDA: | ||||||||||||||||||||
EBITDA | $ | - | $ | (1,199 | ) | $ | 1,153 | $ | (1,350 | ) | $ | (1,396 | ) | |||||||
Stock based compensation | - | 598 | - | 225 | 823 | |||||||||||||||
Dividend income from GECC | - | - | - | (490 | ) | (490 | ) | |||||||||||||
Unrealized loss on investment in GECC | - | - | - | (39 | ) | (39 | ) | |||||||||||||
Unrecognized incentive fees earned(3) | - | 1,060 | - | - | 1,060 | |||||||||||||||
Non-reimbursable MAST Capital expenses | - | - | - | - | - | |||||||||||||||
Broken deal expenses(6) | - | - | - | 413 | - | |||||||||||||||
Re-measurement of warrant liability | - | - | - | - | - | |||||||||||||||
Adjusted EBITDA | $ | - | $ | 459 | $ | 1,153 | $ | (1,241 | ) | $ | (42 | ) | ||||||||
For the year ended June 30, 2018 | ||||||||||||||||||||
(Dollar amounts in thousands) |
Durable Medical Equipment(1) |
Investment Management |
Real Estate(7) |
General Corporate |
Total | |||||||||||||||
Net loss - GAAP | $ | - | $ | (4,910 | ) | $ | 83 | $ | (6,679 | ) | $ | (11,506 | ) | |||||||
EBITDA: | ||||||||||||||||||||
Net loss - GAAP | $ | - | $ | (4,910 | ) | $ | 83 | $ | (6,679 | ) | $ | (11,506 | ) | |||||||
Net loss from discontinued operations | - | - | - | 165 | 165 | |||||||||||||||
Interest | - | 217 | 854 | - | 1,071 | |||||||||||||||
Taxes | - | - | - | (329 | ) | (329 | ) | |||||||||||||
Depreciation and amortization | - | 585 | 538 | 1 | 1,124 | |||||||||||||||
EBITDA | $ | - | $ | (4,108 | ) | $ | 1,475 | $ | (6,842 | ) | $ | (9,475 | ) | |||||||
Adjusted EBITDA: | ||||||||||||||||||||
EBITDA | $ | - | $ | (4,108 | ) | $ | 1,475 | $ | (6,842 | ) | $ | (9,475 | ) | |||||||
Stock based compensation | - | 3,487 | - | 938 | 4,425 | |||||||||||||||
Dividend income from GECC | - | - | - | (2,352 | ) | (2,352 | ) | |||||||||||||
Unrealized loss on investment in GECC | - | - | - | 2,714 | 2,714 | |||||||||||||||
Unrecognized incentive fees earned(3) | - | 1,155 | - | - | 1,155 | |||||||||||||||
Non-reimbursable MAST Capital expenses | - | 281 | - | 128 | 409 | |||||||||||||||
Broken deal expenses(6) | - | - | - | 1,141 | 1,141 | |||||||||||||||
Re-measurement of warrant liability | - | 8 | - | - | 8 | |||||||||||||||
Adjusted EBITDA | $ | - | $ | 823 | $ | 1,475 | $ | (4,273 | ) | $ | (1,975 | ) | ||||||||
Media & Investor Contact:
Investor Relations
+1 (617) 375-3006
investorrelations@greatelmcap.com